Amarantus upcoming milestones over next six months

Lympro
• LP-002 Full Data Set from 140 patients (70 AD – mild to severe, 70 HC)
• Assay Validation at Icon
• IUO Launch
• CLIA Approval
• CE Mark
• Spin-off / monetization

Eltoprazine
• IND Submission/approval
• Phase 2b Initiation in PD LID
• Full enrollment
• Full data set
• End of Phase 2 meeting in Adult ADHD

MANF
• Orphan Drug Designation (ODD) in RP w/FDA
• ODD applications w/FDA in 2nd retinal indication and RP w/EMA
• Drug Delivery Data in Parkinson’s disease
• Initiation GMP Manufacturing
• Wolfram’s Research Collaboration

ESS
• Close deal with Lonza for Engineered Skin Substitute for the Treatment of Severe Burns
• Initiate Phase 1/2a clinical trial

Company
• Strengthen Management Team
• Strengthen Board of Directors

Dec 13, 2014 - http://content.stockpr.com/amarantus/media/3b...121792.pdf